diagnosis of primary breast cancer and active prescription of tamoxifen or aromatase inhibitors
Not being treated with adjuvant endocrine therapy earlier (except voor neo-adjuvant endocrine therapy)
started with adjuvant endocrine therapy in the last 4 weeks OR already taking adjuvant endocrine therapy (\>=3 months; remaining treatment duration minimal 2 years)
age minimal 18 years
Able to come to the outpatient ward of the hospital for appointments with the nurse or nurse practitioner
Able to understand Dutch or having the possibility to bring someone who translates
You may not be if
Not able to sign informed consent.
Currently being treated with neo adjuvant endocrine therapy
distant metastases proven by a positron emission tomograph (PET) scan with fluordeoxyglucose (FDG) scan
Other invasive malignancy, except for a malignancy being treated without chemotherapy more than 5 years ago and without evidence for recurrence. Patients with basal cell or plaveisel cell skin cancer are eligible for the study.
Participation in another interventional study for adherence or physical activity
Treatment with ovarian suppression
Clareo Health | Adherence Improving Self-Management Strategy (AIMS) in Breast Cancer Patients Using Adjuvant Endocrine Treatment (AET)
